ESMO 2023 Highlights: Early Stage NSCLC, SCLC, Thymic Carcinoma

episode

Lung Cancer Considered not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

MORNING TEA: Harry & Meghan's Brutal SNL Roast, Lady Gaga's Baby News & Dakota Johnson's New Man 8 min · 13 Sep 2026 · The Spill

"I don't think they have enough match winners."| First Thoughts - Brisbane vs Adelaide (14.09.26) 15 min · 13 Sep 2026 · SEN Breakfast

Report any issue

Source

Recorded01 Nov 2023

Publisherfeeds.soundcloud.com ↗

Handlerec:2151588

Show notes

Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CheckMate816, Keynote 671 overall survival results, and Checkmate77T, first perceptions about the data, remaining unanswered questions and how to incorporate to our clinical practice. Further, we discussed exciting data in the 2nd line setting for Small-Cell Lung Cancer and a new potential therapeutic option for thymic carcinoma. Tune in for this thought-provoking, data-driven, and practical episode of Lung Cancer Considered.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in